Sponsors (10)
The resolution promotes better diagnostics, awareness, and research coordination for glioblastoma—potentially improving care and trial development—but it provides no funding or enforceable policy changes, so benefits may be limited and affordability and access remain unresolved.
Patients with suspected or confirmed glioblastoma and their clinicians: clearer molecular diagnostic criteria and biomarker testing guidance that can improve diagnostic accuracy and enable more targeted treatment decisions.
Patients with glioblastoma and the cancer research community: greater coordination and NCI Genomic Trials Network (GTN) support for preclinical and early‑phase trials could accelerate development of new therapies and clinical testing pathways.
Families and caregivers of people with glioblastoma: increased public awareness could lead to earlier symptom recognition and improved caregiver support.
Patients, caregivers, and researchers: the resolution does not allocate funding or establish new programs, so it provides no direct new resources to support research, trials, or patient care.
Middle-class families and patients: highlighting high out-of-pocket costs without changing insurance rules or providing financial relief leaves affordability gaps unaddressed.
Patients and caregivers: emphasizing findings and awareness without accompanying policy action could raise expectations for immediate treatment advances or benefits that the resolution itself does not deliver.
Based on analysis of 2 sections of legislative text.
Expresses findings about the severity and unmet needs of glioblastoma in the United States, noting rising diagnoses, very low survival rates, high patient out-of-pocket costs, limited FDA-approved therapies, and recent changes to molecular diagnostic criteria. The resolution highlights the role of the National Cancer Institute’s Glioblastoma Therapeutics Network (GTN) and calls for greater public awareness and recognition of patients and caregivers, without creating legal requirements or funding.
Introduced June 17, 2025 by Lindsey O. Graham · Last progress June 17, 2025